Millennium Management’s Jounce Therapeutics JNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-500,000
Closed -$925K – 7089
2023
Q1
$925K Sell
500,000
-1,328,681
-73% -$1.65M ﹤0.01% 4164
2022
Q4
$2.03M Buy
+1,828,681
New +$2.6M ﹤0.01% 3551
2022
Q3
– Sell
-82,739
Closed -$251K – 7698
2022
Q2
$251K Buy
+82,739
New +$402K ﹤0.01% 5507
2022
Q1
– Sell
-69,540
Closed -$581K – 7832
2021
Q4
$581K Sell
69,540
-171,685
-71% -$1.41M ﹤0.01% 4923
2021
Q3
$1.79M Sell
241,225
-217,091
-47% -$1.34M ﹤0.01% 4052
2021
Q2
$3.12M Buy
458,316
+280,088
+157% +$2.33M ﹤0.01% 3383
2021
Q1
$1.83M Buy
178,228
+130,333
+272% +$1.43M ﹤0.01% 3619
2020
Q4
$335K Buy
47,895
+24,966
+109% +$194K ﹤0.01% 4489
2020
Q3
$187K Buy
22,929
+7,184
+46% +$44.5K ﹤0.01% 4087
2020
Q2
$109K Sell
15,745
-50,381
-76% -$272K ﹤0.01% 3970
2020
Q1
$314K Buy
66,126
+1,837
+3% +$10.6K ﹤0.01% 3153
2019
Q4
$561K Sell
64,289
-94,294
-59% -$510K ﹤0.01% 3315
2019
Q3
$528K Buy
+158,583
New +$635K ﹤0.01% 3224
2019
Q1
– Sell
-218,024
Closed -$735K – 4431
2018
Q4
$735K Sell
218,024
-422,237
-66% -$1.97M ﹤0.01% 2743
2018
Q3
$4.16M Sell
640,261
-38,916
-6% -$289K 0.01% 1942
2018
Q2
$5.2M Buy
679,177
+433,281
+176% +$6.25M 0.01% 1789
2018
Q1
$5.5M Sell
245,896
-125
-0.1% -$2.77K 0.01% 1741
2017
Q4
$3.14M Buy
246,021
+186,068
+310% +$2.74M ﹤0.01% 2001
2017
Q3
$934K Sell
59,953
-144,793
-71% -$2.05M ﹤0.01% 2558
2017
Q2
$2.87M Sell
204,746
-89,116
-30% -$1.91M 0.01% 1856
2017
Q1
$6.46M Buy
+293,862
New +$6.23M 0.01% 1298

Other funds holding JNCE

Millennium Management's JNCE Position: Q2 2023 in Review

Millennium Management sold out of Jounce Therapeutics (JNCE) in Q2 2023, closing a stake of 500,000 shares — an estimated $925K sold.

Millennium Management first reported a position in JNCE in Q1 2017 and held it in 21 quarters. The position peaked at $6.46M in Q1 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Millennium Management reported no remaining Jounce Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Millennium Management sold 500,000 Jounce Therapeutics shares in Q2 2023, an estimated $925K.
  • Millennium Management first reported a position in Jounce Therapeutics in Q1 2017 and held it in 21 quarters.
  • Millennium Management's Jounce Therapeutics position peaked at $6.46M in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.